Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis

Table 4 Overall and subgroup analysis of SNHG16 for OS in human cancers

Variables	Studies	Patients	Model	HR (95% CI)	P-value	Heterogeneity
Variables	Studies	Patients	Model	HR (95% CI)	P-value	I²(%)	χ2	P-value
OS	14	1148	Fixed	1.866 (1.571–2.216)	0.000	25.8	17.52	0.176
Extract method
Data in paper	5	578	Random	2.912 (1.729–4.906)	0.000	70.40	13.5	0.009
Survival curves	9	570	Fixed	1.571 (1.155–2.135)	0.004	0.00	2.26	0.972
Method
qRT-PCR	13	1087	Fixed	1.830 (1.538–2.177)	0.000	20.2	15.04	0.239
ISH	1	61	–	4.985 (1.451–17.129)	0.011	–	–	–
Cancer type
Urinary System	2	321	Fixed	2.523 (1.540–4.133)	0.000	0.0	0.0	0.955
Digestive System	6	411	Fixed	2.406 (1.556–3.721)	0.000	0.0	3.89	0.566
Reproductive system	2	141	Fixed	1.592 (0.948–2.674)	0.079	0.0	0.32	0.575
Musculoskeletal system	2	161	Fixed	1.274 (0.727–2.233)	0.398	0.0	0.01	0.910
Other	2	114	Fixed	1.786 (1.406–2.267)	0.000	87.9	8.30	0.004

Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, OS overall survival, qRT-PCR quantitative reverse transcription polymerase chain reaction, ISH in situ hybridization

ISSN: 1471-2407